This study provides compelling clinical evidence that vitamin D supplementation exerts significant anti‐inflammatory and antioxidant effects in MS patients, as evidenced by the reduction in serum CHI3L1, MDA, and TOS, and the increase in TAC, SOD, CAT, and GPx activity following an 8‐week intervention. The gene discussed is SOD1; the disease is myeloid sarcoma.